Abstract
A3 adenosine receptors (ARs) have long been viewed as potential therapeutic targets due to their association with a variety of pathophysiological processes. Development of potent and selective A3AR nucleoside ligands has been an area of interest of medicinal chemists since last two decades. Various prime modifications made on N6 and C-2 position of the adenosine moiety has led to the discovery of some of the most efficacious A3AR ligands. This review is an account of the development of 4'-thionucleosides as A3AR agonists and antagonists by various chemical modifications on the thionucleoside template.
Keywords: A3 adenosine receptor, agonist, antagonist, 4’-thionucleoside, structure-activity relationship.
Graphical Abstract
Current Organic Chemistry
Title:4'-Thionucleosides as Potent and Selective A3 Adenosine Receptor Ligands
Volume: 20 Issue: 8
Author(s): Pramod K. Sahu, Siddhi D. Naik, Sofia Mehdi and Lak S. Jeong
Affiliation:
Keywords: A3 adenosine receptor, agonist, antagonist, 4’-thionucleoside, structure-activity relationship.
Abstract: A3 adenosine receptors (ARs) have long been viewed as potential therapeutic targets due to their association with a variety of pathophysiological processes. Development of potent and selective A3AR nucleoside ligands has been an area of interest of medicinal chemists since last two decades. Various prime modifications made on N6 and C-2 position of the adenosine moiety has led to the discovery of some of the most efficacious A3AR ligands. This review is an account of the development of 4'-thionucleosides as A3AR agonists and antagonists by various chemical modifications on the thionucleoside template.
Export Options
About this article
Cite this article as:
K. Sahu Pramod, D. Naik Siddhi, Mehdi Sofia and S. Jeong Lak, 4'-Thionucleosides as Potent and Selective A3 Adenosine Receptor Ligands, Current Organic Chemistry 2016; 20 (8) . https://dx.doi.org/10.2174/1385272819666150804000511
DOI https://dx.doi.org/10.2174/1385272819666150804000511 |
Print ISSN 1385-2728 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5348 |
Call for Papers in Thematic Issues
Catalytic C-H bond activation as a tool for functionalization of heterocycles
The major topic is the functionalization of heterocycles through catalyzed C-H bond activation. The strategies based on C-H activation not only provide straightforward formation of C-C or C-X bonds but, more importantly, allow for the avoidance of pre-functionalization of one or two of the cross-coupling partners. The beneficial impact of ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Floating Drug Delivery Systems for Prolonging Gastric Residence Time: A Review
Current Drug Delivery Pattern Recognition by CD6: A Scavenger-Like Lymphocyte Receptor
Current Drug Targets New Molecular Targets of Anticancer Therapy – Current Status and Perspectives
Current Medicinal Chemistry Is Small Really Beautiful? Nanosensors and Low Abundance Biomarkers for Personalized Medicine
Current Pharmacogenomics and Personalized Medicine Recognition of Nucleic Acids by Toll-Like Receptors and Development of Immunomodulatory Drugs
Current Medicinal Chemistry Curcumin and Liver Cancer: A Review
Current Pharmaceutical Biotechnology Advantages of Multidetector CT Cystoscopy in the Detection of Bladder Tumors
Current Medical Imaging Hydrogen Sulfide Generation in Mammals: The Molecular Biology of Cystathionine-β-Synthase (CBS) and Cystathionine-γ-Lyase (CSE)
Inflammation & Allergy - Drug Targets (Discontinued) Radiopharmaceuticals Labelled with Copper Radionuclides: Clinical Results in Human Beings
Current Radiopharmaceuticals Pharmacological Management of Psychosis in Parkinson Disease: A Review
Current Drug Therapy Engineered Nanoparticles in Cancer Therapy
Recent Patents on Drug Delivery & Formulation The HOX Gene Network as a Potential Target for Cancer Therapy
Current Cancer Therapy Reviews Contextualizing the Genes Altered in Bladder Neoplasms in Pediatric and Teen Patients Allows Identifying Two Main Classes of Biological Processes Involved and New Potential Therapeutic Targets
Current Genomics TGF-Beta Type I Receptor (Alk5) Kinase Inhibitors in Oncology
Current Pharmaceutical Biotechnology Genetic Variation at the Human MGMT Locus and its Biological Consequences
Current Pharmacogenomics Pharmacological Countermeasures for the Acute Radiation Syndrome
Current Molecular Pharmacology Small Players With Big Roles: MicroRNAs as Targets to Inhibit Breast Cancer Progression
Current Drug Targets Biomarkers of Angiogenesis and their Role in Patient Selection for Antiangiogenic Therapy
Current Angiogenesis (Discontinued) Association of N-Acetyltransferase-2 Genotypes and Anti-Tuberculosis Induced Liver Injury: First Case-Controlled Study from Iran
Current Drug Safety Pharmaceutical Strategies Enhancing Cell Penetration Efficiencies of Non-Viral Gene Delivery Systems
Current Gene Therapy